top of page

Bridging science
& business

We are i&i Bio. Partners of outstanding founders on a mission to change how patients are treated.

About Us

Embedded in the innovative ecosystem around the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Science, we are one of the very few VC funds in Europe focused exclusively on life science ventures.

areal uochb.jpg

We back Europe’s next wave of early-stage startups that address unmet medical needs through strong science and a competitive edge. We look for founders with a clear edge and the drive to take their innovations global.

Strategy

We are here to support your journey from the very start. Because for us, it is never too early to meet bold ideas.

Stage

Ready to create? We can start at €150k to support business creation. Ready to grow? Our sweet spot lies between €0.5M and €2M. Being exceptional? We keep a possibility of extra funding for our unicorn portfolio.

Region

While our primary focus is on Central and Eastern Europe, we are open to collaborating with ambitious teams from all over the Europe.

Focus

As a life sciences fund, we are comfortable with drug discovery, medtech, diagnostics, and AI verticals.

Portfolio

NAME
YEAR
FIELD

2021

drug discovery

2022

drug discovery, AI

2022

diagnostics

2022

drug discovery

2022

drug discovery

2022

diagnostics

2022

medtech

2023

diagnostics

2023

medtech

2023

drug discovery

2024

medtech

2024

drug discovery, AI

2024

drug discovery

2024

drug discovery, AI

2024

drug discovery

2025

drug discovery

Team

DSCF0553.jpg

Founding Partner

Karel Kubias, MBA

Karel has over 20 years of leadership experience in life sciences, pharma, and diagnostics companies. He has held executive and board roles, including CEO of Merck’s Czech subsidiary and later Head of the EEMEA region at Merck Millipore.

DSCF0766.jpg

Founding Partner

Ivan Vohlmuth

Ivan has over 25 years of experience in fund management, VC, and PE. He has overseen the allocation and exit of 100+ investments across CEE and the Baltics and has held more than 30 executive and non-executive board positions across industries.

BS i&i Bio.png

Partner

Barbora Šumová, Ph. D.

Barbora is focusing on investments in innovative biotech and medtech ventures. She brings several years of experience in venture capital, startup creation, portfolio management, and board leadership. She holds a Ph.D. in Immunology.

DSCF0732.jpg

Founding Partner

Tomáš Maršálek, MBA

Tomáš has over 15 years of experience in fund management, venture capital, and private equity. He has also served as CFO in several SMEs. His expertise includes valuations, due diligence, and tax structuring. He is a member of the Association of Chartered Certified Accountants.

eb95dad3-2742-4274-b55c-3b55c1837831.png

Advisor

Magdalena Marciniak

Magdalena is a manager with over 10 years of experience in healthcare, biotech, and FMCG. She specializes in business development, commercialization, and strategic partnerships. She is a Ph.D. candidate in project management at Cracow University of Economics.

DSCF0514-Edit.jpg

Scientific Analyst

Pavlína Koutecká

Pavlína is a computer scientist with expertise in AI and techbio sectors.  She has built several projects at the intersection of AI, life sciences, and healthcare. Before joining the fund, she contributed to research in mathematical optimization.

DSCF0421.jpg

Communications Manager

Martin Kovalčík

Martin worked as media coordinator at Czech non-profit organization People in Need, managing media services for a 300-member team. He also has editorial experience, most notably at Metro newspaper, where he spent over five years, including two as deputy editor-in-chief

DSCF0934-Edit.jpg

Office Manager

Simona Šandová

Simona has worked as Office Manager and Junior Property Manager, handling training and  conference organization, client and supplier communication, and administrative support for project and property departments. She brings strong experience in administration and office management.

Latest News

HeartBeat.bio Joins Forces with Boehringer Ingelheim to Advance Gene Therapies for Inherited Heart Muscle Disorders

22. 9. 2025

KyDo Therapeutics Announces €4.45 Million Seed Financing to Advance its Covalent-Allosteric Inhibitor Platform to Address Highly Unmet Medical Needs in Oncology

16. 9. 2025

iQure Pharma Secures $4M Funding Advancing Phase 1 Clinical Trial for iQ-007

7. 1. 2025

bottom of page